"Amifostine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
| Descriptor ID |
D004999
|
| MeSH Number(s) |
D02.705.400.625.050 D02.705.539.345.050 D02.886.300.692.050
|
| Concept/Terms |
Amifostine- Amifostine
- Amifostine Trihydrate
- Trihydrate, Amifostine
- APAETP
|
Below are MeSH descriptors whose meaning is more general than "Amifostine".
Below are MeSH descriptors whose meaning is more specific than "Amifostine".
This graph shows the total number of publications written about "Amifostine" by people in this website by year, and whether "Amifostine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amifostine" by people in Profiles.
-
Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A, von Hoff D, Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009 Jan 01; 27(1):127-45.
-
Levi M, Knol JA, Ensminger WD, DeRemer SJ, Dou C, Lunte SM, Bonner HS, Shaw LM, Smith DE. Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. Drug Metab Dispos. 2002 Dec; 30(12):1425-30.
-
Bonner HS, Shaw LM. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol. 2002 Feb; 42(2):166-74.
-
Bonner HS, Shaw LM. Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000 Mar 10; 739(2):357-62.
-
Shaw LM, Bonner HS, Schuchter L, Schiller J, Lieberman R. Pharmacokinetics of amifostine: effects of dose and method of administration. Semin Oncol. 1999 Apr; 26(2 Suppl 7):34-6.
-
Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin Oncol. 1996 Aug; 23(4 Suppl 8):18-22.
-
Ben-Josef E, Mesina J, Shaw LM, Bonner HS, Shamsa F, Porter AT. Topical application of WR-2721 achieves high concentrations in the rectal wall. Radiat Res. 1995 Jul; 143(1):107-10.
-
Shaw LM, Bonner HS, Brown DQ. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos. 1994 Nov-Dec; 22(6):895-902.
-
Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC, McCulloch W, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 1994 Jun 01; 83(11):3132-7.
-
Shaw LM, Glover D, Turrisi A, Brown DQ, Bonner HS, Norfleet AL, Weiler C, Glick JH, Kligerman MM. Pharmacokinetics of WR-2721. Pharmacol Ther. 1988; 39(1-3):195-201.